SCHEMBL29189103

SCHEMBL29189103

CN1CCC[C@@H](N(C)c2nnc(Cl)c3ccccc23)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.40
MEN1 O00255 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GSK3B P49841 5/20 0.38
JAK2 O60674 2/20 0.36
JAK3 P52333 2/20 0.36
KAT2B Q92831 1/20 0.36
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
ADRA1B P35368 1/20 0.35
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
LSS P48449 1/20 0.34
DRD2 P14416 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24840031 1.00 SIGMAR1 (0.40) SIGMAR1MEN1GFERKMT2APOLB
SCHEMBL31359742 1.00 SIGMAR1 (0.40) SIGMAR1MEN1GFERKMT2APOLB
SCHEMBL26115121 0.84 KMT2A (0.50) SIGMAR1MEN1KMT2APOLBTSHR
SCHEMBL29189098 0.82 JAK1 (0.42) MEN1GFERKMT2AGSK3BJAK2
SCHEMBL29189096 0.82 JAK1 (0.42) MEN1GFERKMT2AGSK3BJAK2
SCHEMBL30718319 0.81 JAK1 (0.40) SIGMAR1JAK2JAK3
SCHEMBL30718299 0.81 JAK1 (0.40) SIGMAR1JAK2JAK3
SCHEMBL26115853 0.78 NPSR1 (0.50) MEN1KMT2ATSHRMAPK1SMN1; SMN2
SCHEMBL30168043 0.78 PRMT5 (0.46) MEN1KMT2APOLBJAK2HTR6
SCHEMBL24840030 0.78 PRMT5 (0.46) MEN1KMT2APOLBJAK2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327413-A1 NLRP3 MODULATORS ZOMAGEN BIOSCIENCES LTD 2024-10-03 US disclosed
EP-4362946-A1 NLRP3 MODULATORS Zomagen Biosciences Ltd (US) 2024-05-08 EP disclosed
CN-117881401-A NLRP3 modulators 祖玛珍生物科学有限公司 2024-04-12 CN disclosed
WO-2023278438-A1 NLRP3 MODULATORS ZOMAGEN BIOSCIENCES LTD (US) 2023-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327413-A1 NLRP3 MODULATORS NLRP3, NLRP1, NOD1 SIGMAR1 1923/4885MEN1 4787/4885GFER 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.